光学制御 ドーパミン受容体 光スイッチ可能な結合逆アゴニスト
Prashant C Donthamsetti1, Nils Winter2, Matthias Schönberger2
1Department of Molecular and Cell Biology, University of California , Berkeley, California 94720, United States.
Journal of the American Chemical Society
|November 23, 2017
まとめ
科学者は光スイッチ可能な結合リンガンを用いてドーパミン受容体 (DAR) を遠隔制御するために設計した. この画期的な発見により GPCRsの正確な時空調節が可能になり 新しい治療戦略が生まれました
科学分野:
- 生物化学
- 分子生物学
- 神経科学
背景:
- 家族AのGタンパク質結合受容体 (GPCR) は,生物学的プロセスと臨床応用において極めて重要です.
- ロドプシン (Rhodopsin) は,A族のGPCRであり,網膜との共性結合により,光に敏感である.
- ほとんどのGPCRは光感度と共性リガンド結合が欠如しており,遠隔制御の可能性を制限しています.
研究 の 目的:
- ロドプシンの光感受性を真似て 遠隔操作で精密に制御する A族のGPCRを設計する
- GPCR活性に対する受容体特異的および細胞型特異的空間時間調節法を開発する.
- ドーパミン受容体 (DAR) を制御する光スイッチ可能結合体 (PTLs) の可能性を調査する.
主な方法:
- ドーパミン受容体リガンド (PPHT) のアゾベンゼン誘導体と,ドーパミン結合部位近くの合成システイン残基の結合.
- ドーパミンD1およびD2受容体 (D1RおよびD2R) の迅速で可逆で選択的な阻害を達成するためにPTLを使用します.
- 光スイッチ可能な結合性中性抗体または結合部位に基づく逆アゴニストとしてのリガンドの行動を調査する.
主要な成果:
- 光による選択的な遠隔操作のためのDARの成功化学工学.
- PTLを使用したD1RとD2Rの迅速で可逆で選択的なブロックが実証された.
- PTL結合部位による様々なリガンド活性 (対抗体または逆抗体) が観察された.
結論:
- ドーパミン受容体は,光で活性化されたリガンドを使用して,精密なリモート制御のために設計することができます.
- このアプローチは,様々なファミリーAのGPCRの精度制御のための多用途のテンプレートを提供します.
- この発見は,空間時間的な精度でGPCRを標的とした新しい治療戦略の道を開く.
関連する概念動画
01:25Drug-Receptor Interaction: Agonist
4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.0K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.0K
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.2K